Navigation Links
PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
Date:9/30/2008

Panacea Biotec to Make a $13.1 Million Strategic Investment in PharmAthene

ANNAPOLIS, Md., Sept. 30 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has entered into a strategic alliance with Panacea Biotec Ltd., that includes a strategic equity investment in PharmAthene by Panacea Biotec, through its subsidiary, Kelisia Holdings Ltd., of $13.1 million in exchange for the sale of common stock and warrants.

Under the financing, Panacea Biotec's subsidiary has agreed to purchase approximately 3.73 million shares of PharmAthene common stock at a negotiated price of $3.50 per share, which represents a 90% premium above the closing price of PharmAthene's common stock on September 29, 2008. Upon the closing, Panacea Biotec's subsidiary will also receive 12-month warrants to purchase up to approximately 2.75 million additional shares of PharmAthene common stock at an exercise price of $5.10 per share. The transaction is expected to close on or before October 20, 2008.

"Our agreement with Panacea Biotec is part of a comprehensive strategy to strengthen our balance sheet and forge a strategic alliance with a globally recognized biopharmaceutical company," said David P. Wright, President and Chief Executive Officer of PharmAthene. "We were attracted to Panacea Biotec because it has distinguished itself as an international health management company that is actively conducting research and development of novel chemical and biological pharmaceutical formulations and has developed a diverse proprietary product portfolio encompassing pediatric vaccines and therapeutics for emerging infectious diseases and othe
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Shimadzu ... Liquid Chromatograph (2D-LC), which offers a powerful ... matrices. The system provides a new level ... which is beneficial to scientists analyzing pharmaceutical ... natural products. , Comprehensive 2D-LC combines two ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... have been approved for trading in the ... Trading is expected to commence on September 17, 2014 ... will continue to trade on the TSX Venture Exchange ...
(Date:9/17/2014)... Angeles, CA (PRWEB) September 17, 2014 Escape ... microchip for pets which will alert owners if their pet ... using GPS from an implanted microchip in the pet’s body. ... implantable microchips for pets have been around for many years, ... and are not able to track a pet’s location or alert ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... CROSSE, Wis., Dec. 8, 2011  Prem Rabindranauth, MD, a heart ... in La Crosse, Wis., is using an exciting ... perform heart bypass surgery. To perform MICS, a very small ... cut through the breast bone that is needed with traditional ...
... WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis ... its corporate presentation at the Oppenheimer 22nd Annual Healthcare ... 2011. The Company is scheduled to present ... Time.  The presentation will be webcast live and will ...
... Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it ... University of Utah.  Pursuant to the agreement, the University ... derived from stem cells. The agreement ... strategic collaboration between BRT and the University of Utah, ...
Cached Biology Technology:Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference 2BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah 2
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... at the Catalan Institute of Oncology-Bellvitge Biomedical Research ... 5 genes differentially expressed in normal accompanying cells ... be used to classify colorectal tumors, predict the ... clinical decisions to prevent relapses. , Biomarkers ... common in our population considering both sexes. About ...
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2Coral growth rate plummets in 30-year comparison 2
... clinical trial to test a revolutionary treatment for blindness ... (University College London). The trial, funded by the Department ... could have a significant impact on future treatments for ... and children who have a condition called Leber’s congenital ...
... are an integral part of African culture, one of ... South Africa, 21st century drug therapy is used side-by-side ... plants have been used in African medicine to treat ... of the purported benefits of many plants is still ...
... brain study, even people who seemed resilient but were close to ... 11, 2001, have brains that are more reactive to emotional stimuli ... is the finding of a new Cornell study that excluded people ... (PTSD) or major depression. One of the first studies to look ...
Cached Biology News:First clinical trial of gene therapy for childhood blindness 28 plants from South Africa may hold potential for treating high blood pressure 28 plants from South Africa may hold potential for treating high blood pressure 38 plants from South Africa may hold potential for treating high blood pressure 4Traumas like Sept. 11 make brains more reactive to fear 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: